CAR T-cell - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug regulator.

US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy

Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.